State Street Corp Increases Position in Eli Lilly and Company $LLY

State Street Corp increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,215,754 shares of the company’s stock after purchasing an additional 605,752 shares during the period. Eli Lilly and Company accounts for 0.9% of State Street Corp’s portfolio, making the stock its 18th largest holding. State Street Corp owned 3.85% of Eli Lilly and Company worth $43,438,262,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $25,000. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $30,000. Maseco LLP grew its position in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $39,000. Finally, Aventus Investment Advisors Inc. lifted its holdings in Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after purchasing an additional 27 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on LLY. Sanford C. Bernstein upped their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Wednesday, September 9th. Guggenheim upped their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 23rd. Finally, HSBC lifted their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,305.25.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $5.12 during midday trading on Tuesday, reaching $1,170.01. 1,111,489 shares of the stock traded hands, compared to its average volume of 3,013,810. The company’s 50 day moving average is $1,176.50 and its 200 day moving average is $1,078.33. Eli Lilly and Company has a one year low of $712.05 and a one year high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock has a market capitalization of $1.10 trillion, a PE ratio of 39.28, a P/E/G ratio of 1.42 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 36.54 earnings per share for the current year.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly CEO David Ricks said approximately 700,000 seniors have started GLP-1 treatments since Medicare coverage began in July, with Lilly capturing about 70% of those new patients. Foundayo also represents roughly one-third of new oral GLP-1 prescriptions, with its share growing weekly. CNBC Medicare coverage article
• Positive Sentiment: Lilly broke ground on a planned $6.5 billion Houston manufacturing facility that will produce active ingredients for medicines including Foundayo. The project is expected to create more than 600 jobs and strengthen domestic supply capacity. Lilly Houston manufacturing announcement
• Positive Sentiment: Investor Ken Langone said Lilly is becoming one of the largest positions in his portfolio and suggested the stock could eventually reach $2,000. Separately, a major global bank reportedly sees approximately 37% upside after the recent pullback. Ken Langone Lilly outlook
• Neutral Sentiment: Lilly and Dragoneer have indicated interest in Oura’s planned IPO. The investment could provide exposure to consumer health data, but it is not expected to materially affect Lilly’s near-term earnings. Oura IPO article
• Negative Sentiment: Competition remains the principal risk. Viking Therapeutics shares surged after positive obesity-drug data, while Roche also reported encouraging results. The developments raise concerns that Lilly’s current obesity-drug dominance could face stronger competition, pressuring the stock alongside Novo Nordisk. Viking and Roche obesity-drug data

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last three months. Insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.